Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
0.9% saline solution nasal spray
- Development stage
- Unknown
- Lead developer
- Rupert Lanzenberger
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
0.9% saline solution nasal spray is an isotonic sterile aqueous solution of sodium chloride (0.9% w/v) formulated for intranasal administration. In clinical trials, such as the Phase 1 study led by Rupert Lanzenberger at the Medical University of Vienna investigating intranasal esketamine's effects on attentional brain networks, it is commonly utilized as an inert placebo comparator. As a placebo, it contains no pharmacologically active ingredients other than sodium chloride and water, lacks a specific biological target, and serves as a blinded control to assess the efficacy and safety of active intranasal therapeutics.
- Other names
- 0.9% sodium chloride nasal spraynormal saline nasal spraysaline nasal spraysaline solution nasal spray
Beyond the preview
Go deeper on 0.9% saline solution nasal spray.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 0.9% saline solution nasal spray.